Dudediligence.

Nurix Therapeutics, Inc

NRIXNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$12.6MAug ’24$13.3MNov ’24$18.5MFeb ’25$44.1MMay ’25$7.9MAug ’25$13.6MNov ’25$6.3MFeb ’26$9.0MMay ’26
Net income, by quarter
−$49.0MAug ’24−$58.5MNov ’24−$56.4MFeb ’25−$43.5MMay ’25−$86.4MAug ’25−$78.2MNov ’25−$87.2MFeb ’26−$89.5MMay ’26
Fiscal years, by the month each ended
LineNov 2021Nov 2022Nov 2023Nov 2024Nov 2025
Revenue$29.8M$38.6M$77.0M$54.5M$84.0M
Operating income−$117.9M−$183.9M−$155.1M−$213.0M−$285.7M
Net income−$117.2M−$180.4M−$143.9M−$193.6M−$264.5M
Operating cash flow−$84.4M−$159.8M−$81.4M−$172.6M−$249.5M
Free cash flow−$90.0M−$172.1M−$89.8M−$181.9M−$263.5M
Cash$80.5M$64.5M$54.6M$110.0M$247.0M
Shares outstanding44.7M47.2M48.7M75.9M101.8M